Welcome to our dedicated page for Kinnate Biopharma news (Ticker: KNTE), a resource for investors and traders seeking the latest updates and insights on Kinnate Biopharma stock.
Kinnate Biopharma Inc. (Nasdaq: KNTE) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focusing on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. Founded in 2018, Kinnate aims to address known oncogenic drivers for which there are currently no approved targeted therapies, and to overcome the limitations of existing cancer treatments, such as non-responsiveness and resistance.
The company's lead product candidate is EXARAFENIB, an investigational pan-RAF inhibitor targeting cancers with BRAF and NRAS-driven alterations. Another key candidate is KIN-3248, designed to treat cancers with FGFR2 and FGFR3 alterations. These candidates are part of the company's broader pipeline driven by the Kinnate Discovery Engine, which prioritizes high selectivity, optimized pharmaceutical properties, broad genetic alteration coverage, overcoming resistance, and brain penetration.
Recent achievements include FDA clearance for the IND application for KIN-7136, a brain-penetrant MEK inhibitor, and ongoing clinical trials for the exarafenib plus binimetinib combination. However, Kinnate has announced a strategic reprioritization plan, pausing the development of KIN-7136 and exploring strategic alternatives for exarafenib monotherapy and KIN-3248.
Financially, Kinnate reported having approximately $204.3 million in cash as of June 2023, projected to fund operations into the second quarter of 2026. Furthermore, the company has announced a workforce restructuring to align with its refined focus, aiming to retain around 28 full-time employees.
In terms of partnerships, Kinnate recently agreed to sell its investigational pan-RAF inhibitor, exarafenib, to Pierre Fabre Laboratories. This agreement is expected to expand the reach of Kinnate’s programs globally and maximize value for shareholders.
For more information, visit Kinnate.com and follow the company on LinkedIn to stay updated on their latest initiatives and corporate developments.
Kinnate Biopharma Inc. (KNTE) has appointed Neha Krishnamohan as Chief Financial Officer and expanded its leadership team amid a growth phase. The company is set to initiate a first-in-human trial of its lead candidate, KIN-2787, and progress additional programs. Krishnamohan, previously at Goldman Sachs, brings over 12 years of experience in healthcare investment banking and has executed transactions exceeding $100 billion. Alongside her, Kinnate introduces several senior leaders from renowned biopharmaceutical companies, aiming to enhance its clinical-stage operations and target underserved cancer treatment populations.
Kinnate Biopharma (Nasdaq: KNTE) announced promising preclinical results for its lead product candidate, KIN-2787, a pan-RAF inhibitor targeting Class I, II, and III BRAF mutations. The findings were showcased at the 57th Annual Meeting of the American Society of Clinical Oncology. KIN-2787 demonstrated significant anti-tumor activity in vitro and in vivo, paving the way for a Phase 1 clinical trial targeting mutant BRAF-driven solid tumors expected to commence mid-2021.
Kinnate Biopharma, a biopharmaceutical company focused on small molecule kinase inhibitors for challenging genomically defined cancers, announced participation in the Goldman Sachs 42nd Annual Global Healthcare Conference. The event is scheduled for June 10, 2021, at 2:10 PM ET. CEO Nima Farzan will present an overview, and the management team will host investor meetings. A live webcast will be available on Kinnate's website. The company aims to enhance targeted therapeutics for underserved populations using its proprietary Kinnate Discovery Engine.
Kinnate Biopharma (Nasdaq: KNTE) announced FDA clearance for its KIN-2787 IND application for treating mutant BRAF-driven solid tumors, initiating a Phase 1 trial expected mid-2021. The company ended Q1 2021 with cash and investments of $383.1 million. Alongside this, Kinnate secured $35 million through Series A financing for a Chinese joint venture aimed at developing oncology candidates. Despite a Q1 net loss of $17.5 million, up from $3.9 million in 2020, Kinnate is advancing its clinical programs, including KIN-3248, anticipating future IND filings.
Kinnate Biopharma Inc. (Nasdaq: KNTE) announced a $35 million Series A financing for a joint venture in Greater China, led by OrbiMed Asia Partners and joined by OrbiMed Private Investments and Foresite Capital. This venture will focus on developing Kinnate's kinase inhibitor candidates, particularly KIN-2787 and KIN-3248, targeting cancers like lung cancer and urothelial carcinoma. Veteran industry executive Wenn Sun, Ph.D., will serve as Executive Chair. The joint venture aims to expand Kinnate's global footprint and improve access to targeted cancer therapies in one of the largest healthcare markets.
Kinnate Biopharma Inc. (Nasdaq: KNTE) announced that pre-clinical data for its RAF inhibitor candidate, KIN-2787, will be presented at the 2021 ASCO Annual Meeting from June 4-8, 2021. The findings highlight KIN-2787's potential in treating actionable RAF mutations not addressed by existing therapies. BRAF mutations are found in about 6% of human cancers, with significant portions classified as Class II and III, which current treatments do not effectively target. A Phase 1 clinical trial for KIN-2787 is expected to begin in 2021, focusing on advanced solid tumors with BRAF alterations.
Kinnate Biopharma (Nasdaq: KNTE) announced that Dr. Stephen Kaldor, a co-founder, will not be nominated for re-election to its Board of Directors at the upcoming annual meeting on June 11, 2021. Dr. Kaldor aims to focus on a new biopharmaceutical start-up. CEO Nima Farzan acknowledged Dr. Kaldor's significant contributions in building the company’s pipeline of kinase inhibitors. Kinnate continues to develop targeted therapies for difficult-to-treat cancers, emphasizing its commitment to underserved patient populations.
Kinnate Biopharma Inc. (Nasdaq: KNTE) completed its IPO, raising $276 million to advance kinase inhibitors for genomically defined cancers. The company is on track for an IND filing for KIN-2787, a RAF inhibitor, in the first half of 2021, aiming to initiate a Phase 1 trial later this year. Additionally, KIN-3248 has been selected as the lead FGFR inhibitor candidate, with an IND filing anticipated in early 2022. Kinnate reported a 2020 net loss of $35.8 million and had approximately $396.9 million in cash at year-end.
Kinnate Biopharma (Nasdaq: KNTE) has been added to the Russell 2000 Index as of March 19, 2021, following its successful IPO in December 2020. This inclusion is viewed as a significant milestone, reflecting the company’s progress in developing targeted cancer therapies. The Russell 2000 Index represents approximately 10% of the total market capitalization of the Russell 3000 Index and is used widely by investment managers and institutional investors for benchmarking. Kinnate aims to expand access to targeted therapeutics for underserved cancer populations.
Kinnate Biopharma Inc. (Nasdaq: KNTE) has announced its participation in upcoming investor conferences in February 2021. CEO Nima Farzan will present at the Goldman Sachs West Coast Biotech Bus Tour on February 22, 2021, and the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. Both events are virtual, and investor meetings will also be hosted during the latter conference. A live webcast of the SVB Leerink presentation will be available on Kinnate's website, with a replay accessible for 30 days post-event.
FAQ
What is the market cap of Kinnate Biopharma (KNTE)?
What does Kinnate Biopharma Inc. specialize in?
What are Kinnate's lead product candidates?
Where is Kinnate Biopharma headquartered?
What recent achievements has Kinnate reported?
What strategic changes has Kinnate made recently?
What is Kinnate's financial condition?
What recent partnerships has Kinnate entered into?
How many employees does Kinnate plan to retain?
Where can I find more information about Kinnate Biopharma?
What is the Kinnate Discovery Engine?
